$FLNA News
Last published 6d ago
- 6d agoFLNAFILANA THERAPEUTICS, INC. - PRESS RELEASEEarnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoFLNAFilana Therapeutics Reports Q3 2026 Financial Results and Provides Business UpdateGlobeNewswire– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells1 provides new insights into simufilam’s
- 2w agoFLNAFilana Therapeutics Announces Publication in Cells of Promising Preclinical Findings for Simufilam in TSC2-Deficient CellsGlobeNewswireFindings provide new insight into simufilam’s effects on cellular stress responses and mitochondrial function New research demonstrates a 37% reduction in elevated ATF4, consistent with attenuation of the
- 1mo agoFLNAFilana Therapeutics to Participate in the 2026 Maxim Growth SummitGlobeNewswireAUSTIN, Texas, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, ", Filana Therapeutics", , the ", Company", )), a biotechnology company currently focused on developing
- 3mo agoFLNADid Filana Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireShareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
- 3mo agoFLNAFilana Therapeutics Reports Q2 2026 Financial Results and Provides Business UpdateGlobeNewswireAUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing therapies for
- 6mo agoFLNAFilana Therapeutics Reports Q1 2026 Financial Results and Business UpdateGlobeNewswireAUSTIN, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis
- 6mo agoFLNAFilana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIIIGlobeNewswireAUSTIN, Texas, May 05, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ:FLNA, "Filana Therapeutics", the "Company")), a biotechnology company currently focused on developing therapies for Tuberous Sclerosis
- 7mo agoFLNAFilana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam DataGlobeNewswireStudy in a well-accepted mouse model of severe Tuberous Sclerosis Complex (TSC) showed that simufilam attenuated the progression of seizures in a dose-dependent mannerResults confirm and extend previously published
- 8mo agoSAVAFLNACassava Sciences Announces Name Change to Filana Therapeutics, Inc.GlobeNewswireNew corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading under "FLNA" effective